Avirmax CMC Inc., a spin off entity of Avirmax Inc., opened a state-of-the-art clinical good manufacturing practice (GMP), adeno-associated virus vector (AAV) CDMO facility on May 11.

Avirmax has expertise in AAV vector design, engineering, process development, GMP manufacturing, analytical testing and characterization that enable clients to obtain full services in AAV product supply from transgene DNA sequences into final AAV final products. The 20,000 square foot facility containing cGMP suites, developmental and testing laboratories, equipped with single use bioreactors at 50 L, 200 L, and 1000 L production scales can deliver rAAV drug product at 10 vector genome per batch within approximately 200 days starting from a transgene DNA plasmid.

Along with ACI, Avirmax Biopharma Inc. (ABI) has pipelines for genetic medicinal product development in major eye diseases including age-related macular degeneration (AMD) and Glaucoma.

Avirmax president and CEO, Shengjiang (Shawn) Liu, said, “Our team has good experience and knowledge in rAAV technology development and rAAV manufacturing. With our new facility, Avirmax CMC Inc. can deliver high yield and quality vectors efficiently, timely and cost effectively.”